[Venlafaxine and its discontinuation syndrome].
Sierra Santos
L
L
Raigal Martín
Y
Y
Ortega García
A
A
Barriochoa Martínez de Pisón
C
C
Aparicio Jabalquinto
G
G
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D001288:Attention / Q000187:drug effects*; D003511:Cyclohexanols / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008569:Memory Disorders / Q000139:chemically induced*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis*; D000069470:Venlafaxine Hydrochloride; D014792:Visual Acuity / Q000187:drug effects*
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride